Loading...
NPI 1851008296 · Des Plaines, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Fz Medical Group Inc is a clinical medical laboratory provider located in Des Plaines, Illinois. This profile covers 5 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Fz Medical Group Inc |
| Address | 1645 S River Rd Ste 24 |
| City | Des Plaines |
| State | IL |
| ZIP | 60018 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 4, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $15.1M |
| Medicaid | $11.5K |
FZ MEDICAL GROUP INC is listed as a Clinical Medical Laboratory in DES PLAINES, IL and its NPI was enumerated on 2022-11-04 (~4 years ago), indicating roughly four years of public Medicare/Medicaid billing history. The provider reports $15.1M in total Medicare revenue and $11.5K in total Medicaid revenue, showing a large disparity in payer scale.
Medicare revenue is highly concentrated: the precomputed top three Medicare codes account for 90.8% of the provider's Medicare revenue. Those top contributors are 0240U ($8M, 52.8% of Medicare revenue), U0003 ($4.3M, 28.6%), and U0005 ($1.4M, 9.4%), which together dominate the $15.1M Medicare total.
The code mix indicates a laboratory operation heavily focused on SARS-CoV-2 testing and specimen collection: U0003 and U0005 are nucleic acid detection codes for SARS-CoV-2 and G2023 is specimen collection for SARS-CoV-2, while 0240U (no description available) alone accounts for the largest single share of Medicare revenue. This pattern points to a high-throughput diagnostic testing business line rather than a broad outpatient laboratory mix.
FZ MEDICAL GROUP displays national-scale dominance on several Medicare testing codes: 0240U ranks #2 of 184 providers nationally (99th percentile; extreme outlier), U0003 ranks #4 of 973 providers (100th percentile; extreme outlier), U0005 ranks #4 of 1090 providers (100th percentile; extreme outlier), and G2023 ranks #3 of 465 providers (100th percentile; extreme outlier). Those rank and percentile positions indicate the provider bills far above typical national volume for multiple high-revenue COVID-related codes.
In contrast, the provider's Medicaid activity is minimal and concentrated: the precomputed top three Medicaid codes account for 90.9% of Medicaid revenue, with U0003 at $5.9K (51.4% of Medicaid revenue), G2023 at $2.6K (22.8%), and U0005 at $1.9K (16.7%). Medicaid ranks for these codes are around the state median (U0003 rank #160 of 350, 54th percentile; G2023 rank #183 of 396, 54th percentile; U0005 rank #108 of 210, 49th percentile), signifying a modest in-state presence rather than a dominant Medicaid position.
The provider is effectively Medicare-centric: $15.1M of revenue is reported to Medicare versus $11.5K to Medicaid, so Medicare is the overwhelmingly dominant payer for this entity. For payer-mix analysis, treat this as a Medicare-dominated operation with only trace Medicaid billing on file.
Operational scale is evident in claim counts and payment differentials: high Medicare claim volumes such as 57.2K claims for 0240U, 58.6K claims for U0003, 57K claims for U0005, and 60.8K claims for G2023 show large testing throughput on the Medicare side. Average Medicare payments per claim (e.g., $140 for 0240U, $74 for U0003, $25 for U0005, $23 for G2023) are substantially higher than the Medicaid averages reported for the same codes (e.g., $9 for U0003, $3 for U0005, $4 for G2023), highlighting both scale and payer-rate differences.
From a competitive and network-planning perspective, the provider should be treated as a nationally significant source of SARS-CoV-2 testing capacity for Medicare, given multiple "extreme outlier" rankings and very large Medicare revenue concentration. By contrast, its Medicaid footprint is small and comparable to many in-state peers, so contracting or utilization assumptions for Medicaid should reflect a modest local role rather than the national-scale capacity seen in Medicare billing.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 0240U | N/A | 57,160 | $140 | $8M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 58,580 | $70 | $4.3M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 57,030 | $30 | $1.4M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 60,790 | $20 | $1.4M |
| 87420 | The lab analyst performs a test to detect antigens of respiratory syncytial virus, also called RSV, using an immunoassay technique, such as EIA. | 30 | $10 | $390 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 650 | $10 | $5.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 650 | $1 | $2.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 640 | $1 | $1.9K |
| 0240U | N/A | 520 | $1 | $1K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 10 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 160 | 350 | 400 | $70 | $514.7K |
| 0240U | N/A | 9 | 20 | 240 | $120 | $403.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 108 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 183 | 400 | 550 | $20 | $90.8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 58 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Fz Medical Group Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Lifewatch Services, Inc | IL | Physiological Laboratory | $6.3M | $13M |
| Zam Labs LLC | IL | Clinical Medical Laboratory | $62.9K | $9M |
| Nursepower Services Corporation | IL | Nursing Care Agency | $0 | $3.3M |
| Uropartners Surgery Center, LLC | IL | Ambulatory Surgical Clinic/Center | $1.5M | $0 |
| Vlada Nakhlis | IL | Optometrist | $60.9K | $1.1M |
| Montys Clinical Lab LLC | IL | Clinical Medical Laboratory | $411.6K | $534.1K |
| Smartcardia Inc. | IL | Physiological Laboratory | $22.8K | $120.7K |
| Mark Schinsky | IL | Orthopaedic Surgery Physician | $94.1K | $290 |
| Benjamin Domb | IL | Sports Medicine (Orthopaedic Surgery) Physician | $63.4K | $0 |
| Howard Konowitz | IL | Anesthesiology Physician | $26.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.